Global gene editing market, which accrued proceeds worth 4.02 (USD Billion) in 2019, is set to record the CAGR of nearly 14.6% over the period from 2020 to 2026.
Gene Editing Market
The global gene editing market, which accrued proceeds worth 4.02 (USD Billion) in 2019, is set to record the CAGR of nearly 14.6% over the period from 2020 to 2026. The report offers assessment and analysis of the gene editing market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion).
Details of the Report:
2017 and 2018
Earnings provided in terms of USD Billion and CAGR estimated from 2020 to 2026
By Application, By End-User, By Technology, and By Region
North America, Asia Pacific, Latin America, Europe, and the Middle East and Africa
Gene editing is assisting in transformation of basic research in the life sciences and is projected to find plethora of applications in human & animal health, farming & food systems, and the bio-economy. Today, scientists can modify sequences of DNA through insertion or deletion of genes in cells of living organisms. Apparently, the current gene editing methods are safe, effective, and cost-effective and hence have found applications in array of industries. Specifically, two nuclease-based gene-editing technologies, TALE and CRISPR, help scientists to edit genomes with extraordinary precision in a shorter duration. Moreover, these gene editing techniques have provided exact & regulated was for changing crop & animal traits. Furthermore, nuclease-based gene editing is likely to bring revolution in agriculture sector and increase crop yield.
Furthermore, researchers are trying to modify immune cells or T-cells for preventing them from getting infected due to HIV. Scientists are developing various kinds of gene editing methods for treating hemophilia, and engineer T-cells to target & destroy cancer tissues.
Market Growth Drivers
Gene editing is creating a paradigm shift in biotechnology domain. Reportedly, gene editing techniques like CRISPR has the capability of influencing the fields of personalized medicine, cancer research, and healthcare. This, in turn, will built a strong platform for the growth of gene editing market within a span of next few years. Furthermore, gene editing is also used for disease modelling in human beings as well as in gene therapy. It is also utilized for treating heart ailments, viral diseases, inherited eye disorders, hematological ailments. In future, it is also possible to use gene editing tools in cancer immunotherapy, gene diagnostics, and screening of functional genes.
In nuclease-based gene editing, nucleases are used to edit genes. Apparently, nuclease-based gene editing technique finds a slew of applications in the field of biotechnology and is used widely in research & genetic trials as it is cost-effective, easy to perform, and fast. Reportedly, since last few years, TALEN and CRISPR nucleases have enhanced the speed and lowered the cost of gene editing procedures to a larger extent. They have been one of the most vital breakthroughs in the gene editing technologies and are likely to find massive utilization in medical, healthcare, and farming activities. This, in turn, will not only open new vistas of growth for nuclease-based gene editing market, but will favorably influence the gene editing industry over a long run.
Furthermore, nuclease-based gene editing is already being developed for human therapeutics, as a new approach to perform gene therapy and introducing or editing genes to cure diseases. Reportedly, growing progress in creation of programmable nucleases like zinc-finger nucleases, transcription activator-like effector nucleases or TALENs, and Cas9-related nucleases is projected to expedite the growth of gene editing market over the forecast timeline. Apparently, their derivative agents are used as gene editing tools for treating myriad human diseases.
Other very potential gene editing approaches are being developed in the field of immuno-oncology with engineered CAR-T cells directing immune system to fight and eliminate cancer cells. There is an extensive array of potential uses of gene editing techniques in biosynthesis of pharmaceuticals, biofuels, other high-value chemicals, biosensors, bioremediation, and in the food chain. Innovation in the bioeconomy will further augment the gene editing business growth in the near future.
According to the results presented by CRISPR Therapeutics & Vertex Pharmaceuticals before European Hematology Association in June 2020, it was demonstrated that two patients affected due to beta thalassemia and one subject suffering from sickle cell disorder did not require transfusion of blood after their stem cells in the bone marrow were gene edited by using CRISPR technique. This breakthrough is likely to encourage the development of new gene editing therapies for treating various kinds of hereditary diseases in the foreseeable future.
As per NCBI, most clinical utilization of CRISPR gene editing techniques has highlighted on ex vivo gene edition of cells succeeded by the re-introduction of these gene-edited cells again into the subject. The ex vivo editing method has proved to be highly effective for treating many diseases including cancers and sickle cell. However, gene editing can also be applied to diseases requiring cell alteration in vivo.
Moreover, with the rapid evolution of new gene editing procedures, long-lasting or permanent alleviation of genetic disorders through selective modifying of the human genes may become a possibility in the near future, thereby generating huge potential for not only enhancing human health, but also the lifespan of the human beings.
North America To Dominate Overall Market Expansion Over 2020-2026
The growth of the market in North America during the period from 2020 to 2026 is credited to massive acceptance of new gene editing methods in the research institutions in the countries like the U.S. Moreover, favorable laws in the countries like U.S. encouraging gene editing research activities will boost the regional market growth.
Key players influencing market growth include Sangamo Therapeutics, Inc., Lonza Group, Integrated DNA Technologies, Editas Medicine, New England Biolabs, Horizon Discovery Group, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript Corporation, and OriGene Technologies.
The global gene editing market is segmented as follows:
There is an extensive array of potential uses of gene editing techniques in biosynthesis of pharmaceuticals, biofuels, other high-value chemicals, biosensors, bioremediation, and in the food chain, thereby driving the Gene Editing Market by 2026.
The CAGR of the industry is expected to be nearly 14.6% during the forecast timeline.
North America will contribute remarkably towards the global market share over the estimated timeline.
The key market players include New England Biolabs, Thermo Fisher Scientific, CRISPR Therapeutics, Merck KgaA, GenScript Corporation, Sangamo Therapeutics, Inc., Editas Medicine, Integrated DNA Technologies, Lonza Group, Horizon Discovery Group, and OriGene Technologies.